- Home
- HNRG vs PHAR Comparison
HNRG vs PHAR Comparison
Compare HNRG & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- PHAR
- Stock Information
- Founded
- HNRG 1949
- PHAR 1988
- Country
- HNRG United States
- PHAR Netherlands
- Employees
- HNRG N/A
- PHAR N/A
- Industry
- HNRG Coal Mining
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- HNRG Energy
- PHAR Health Care
- Exchange
- HNRG Nasdaq
- PHAR Nasdaq
- Market Cap
- HNRG 632.2M
- PHAR 718.1M
- IPO Year
- HNRG N/A
- PHAR N/A
- Fundamental
- Price
- HNRG $15.32
- PHAR $10.45
- Analyst Decision
- HNRG Strong Buy
- PHAR Strong Buy
- Analyst Count
- HNRG 3
- PHAR 3
- Target Price
- HNRG $18.33
- PHAR $30.00
- AVG Volume (30 Days)
- HNRG 746.0K
- PHAR 2.6K
- Earning Date
- HNRG 08-05-2025
- PHAR 07-31-2025
- Dividend Yield
- HNRG N/A
- PHAR N/A
- EPS Growth
- HNRG N/A
- PHAR N/A
- EPS
- HNRG N/A
- PHAR N/A
- Revenue
- HNRG $410,607,000.00
- PHAR $320,708,000.00
- Revenue This Year
- HNRG N/A
- PHAR $13.31
- Revenue Next Year
- HNRG $9.86
- PHAR $7.68
- P/E Ratio
- HNRG N/A
- PHAR N/A
- Revenue Growth
- HNRG N/A
- PHAR 24.13
- 52 Week Low
- HNRG $4.86
- PHAR $6.65
- 52 Week High
- HNRG $19.71
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- HNRG 38.36
- PHAR 47.51
- Support Level
- HNRG $15.92
- PHAR $10.41
- Resistance Level
- HNRG $16.75
- PHAR $11.50
- Average True Range (ATR)
- HNRG 0.78
- PHAR 0.32
- MACD
- HNRG -0.27
- PHAR -0.17
- Stochastic Oscillator
- HNRG 0.91
- PHAR 2.26
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.